The ‘spin-offs’ of the University of Barcelona obtained around eleven million euros in funding during the year 2023
The spin-offs of the University of Barcelona, companies arising from a technology or knowledge developed at the University, obtained around eleven million euros in funding during the year 2023. This figure represents a significant increase in comparison with previous years, and therefore highlights the ability of these companies to attract investments.
In 2023, participating companies obtained 10.8 million euros of financing, both public and private. It is worth noting the investment round of 1.28 million euros that Oniria Therapeutics received, as well as the obtaining of EIC Accelerator aid, of 2.5 million euros, by Nimble Diagnostics. This funding allows the spin-offs not only to consolidate, but also to expand and innovate, and thus contribute to the creation of new technologies and solutions in various fields such as biotechnology, quantum physics and medicine, among others
During the year 2023 the 26 companies derived from the University invoiced a total of 10.9 million euros, a figure very similar to that achieved the previous year, which was 11.4 million . In this way, the results obtained consolidate the influence and economic impact of the UB spin-offs in the business world and in society. The companies that led the turnover were Enantia, S.L.; Biocontrol Technologies, S.L.; Impetux Optics, S.L.; BeCytes Biotechnologies, S.L.; Nostrum Biodiscovery, S.L., and Qilimanjaro Quantum Tech, S.L.
Beyond their business success, in 2023 the spin-offs of the UB generated more than 270 jobs, with which they have contributed to boosting the economy and creating employment in Catalonia. 30% of these jobs are occupied by former students and university staff of the UB.
Two new spin-offs
The creation of companies is one of the services offered by the Bosch i Gimpera Foundation as a center for the transfer of knowledge, technology and innovation at the University of Barcelona. In 2023, the UB contributed to the creation of two new spin-offs: Disrupt Therapeutics and the Smart Classroom Project. In addition, 16 entrepreneurial projects were advised with the aim of advancing them and becoming viable companies.
Disrupt Therapeutics is a spin-off of the UB and the Pompeu Fabra University (UPF) that focuses on the development of a drug for the prevention of cognitive impairment due to the medicinal use of cannabis.
Smart Classroom Project is a spin-off of the UB and the Open University of Catalonia (UOC) that offers consulting, advisory and training services to centers that want to rethink their learning spaces to use new educational methodologies.
Since 2001, the FBG has contributed to the creation of more than fifty emerging companies. Currently, the University of Barcelona has a total of 26 active companies: Accure Therapeutics (2020), Advanced Nanotechnologies (2012), Aigecko Technologies (2020), Becytes Biotechnologies (2015), Biocontrol Technologies (2004), Bluephage (2016) ), Braingaze (2013), Colorsensing (2018), DapCom Data Services (2013), DBgen Ocular Genomics (2018), Disrupt Therapeutics (2023), Enantia (2003), Gate2Brain (2020), Impetux Optics (2012), Kiin Tech (2015), Kumux (2017), Mind and Identity (2020), Neurekalab (2019), Nimble Diagnostics (2022), Nostrum Biodiscovery (2015), Oniria Therapeutics (2021), Qilimanjaro Quantum Tech (2019), Reveal Genomics (2021) ), Smalle Technologies (2012), Smart Classroom Project (2023) and Virmedex Virtual Experiences (2022).